2022 World Conference on Lung Cancer (ePosters)-EP16.01-007. Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy

EP16.01-007. Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy

Back to course

Pdf Summary

A retrospective study was conducted on patients diagnosed with non-small cell lung cancer (NSCLC) who received immunotherapy treatment at a hospital from July 2015 to January 2021. The study aimed to integrate clinical and molecular information to define molecular subtypes in these patients. The study enrolled 42 patients with a male-female ratio of 3:1 and an average age of 63 years. The most common histology was adenocarcinoma, followed by squamous cell carcinoma. All patients received immunotherapy, with 69% receiving it as second line or later treatment and 30.9% receiving it as first line treatment. The most frequent site of metastasis was the brain, followed by the adrenal glands or bones. Molecular analysis revealed frequent mutations in genes such as TP53, KRAS, MLL2, ATM, BRCA2, and PIK3CA. Subgroup analysis based on metastatic involvement showed some differences in gene mutations, but they did not reach statistical significance, possibly due to the small sample size. Progression-free survival to immunotherapy was evaluated and no statistically significant differences were found based on the most frequent mutations identified. However, patients with mutations in the MLL2 gene seemed to have a better response to immunotherapy. PDL1 50% expression was found to be a favorable factor for survival. Preliminary data suggest the existence of different molecular profiles depending on the site of metastasis, but further studies are needed to validate these findings due to the small sample size.

Asset Subtitle

Laura Gutiérrez Sainz

Meta Tag

Speaker Laura Gutiérrez Sainz

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

retrospective study

non-small cell lung cancer

immunotherapy treatment

molecular subtypes

metastasis

genes

mutation

progression-free survival

response to immunotherapy

molecular profiles